GO:0072757 cellular response to camptothecin: DNA Damage Response Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0072757 describes the cellular response to camptothecin (CPT), a topoisomerase I poison that traps cleavage complexes and generates DNA damage.
• Camptothecin and its derivatives (irinotecan, topotecan) are clinically used anticancer agents, and cellular resistance mechanisms are a major research focus.
• Key response pathways include ATM/ATR-mediated DNA damage signaling, PARP-1 activation, and degradation of WRN helicase by MIB1.
• The response involves cell cycle arrest, apoptosis, senescence, and in some contexts ferroptosis or cuproptosis.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal genes in the camptothecin response.
• EDITGENE provides custom cell models and CRISPR library screening to study GO:0072757 in cancer and other diseases.
Description
The Gene Ontology term GO:0072757, cellular response to camptothecin, defines any process that results in a change in state or activity of a cell as a result of a camptothecin stimulus. Camptothecin (CPT) is a plant alkaloid that specifically targets topoisomerase I, stabilizing the enzyme-DNA cleavage complex and leading to DNA double-strand breaks during replication. This cellular response is critical for understanding the mechanism of action of camptothecin-based chemotherapeutics and for identifying resistance mechanisms in cancer cells. Researchers study GO:0072757 to uncover how cells sense and repair topoisomerase I-mediated damage, and to develop strategies to overcome chemoresistance. The response encompasses DNA damage signaling, cell cycle checkpoints, apoptosis, senescence, and emerging cell death modalities such as ferroptosis and cuproptosis.
cellular response to camptothecin At A Glance
| GO ID | GO:0072757 |
|---|---|
| GO term | cellular response to camptothecin |
| Ontology | biological_process |
| Synonym | cellular response to CPT |
| Major function | Cellular sensing and response to topoisomerase I-mediated DNA damage induced by camptothecin |
| Key pathways | ATM/ATR DNA damage signaling, PARP-1 activation, WRN degradation, apoptosis, senescence, ferroptosis |
| Clinical relevance | Camptothecin derivatives are used in cancer therapy; resistance mechanisms are studied |
| Research tools | CRISPR KO, point mutation, knock-in, overexpression, RNA-seq, proteomics |
What Is GO:0072757?
In our own words, GO:0072757 encompasses all cellular processes triggered by exposure to camptothecin, including changes in gene expression, enzyme activity, cell movement, secretion, and ultimately cell fate decisions such as survival, senescence, or death. It is a biological process term that captures the integrated signaling and effector networks activated when a cell encounters this topoisomerase I inhibitor.
Why Is cellular response to camptothecin Important in Cell Biology?
Understanding GO:0072757 is essential because camptothecin and its derivatives are widely used in cancer chemotherapy, and the cellular response determines drug efficacy and resistance. The pathways activated by camptothecin, such as ATM/ATR signaling and PARP-1-dependent transcription, are also relevant to other DNA-damaging agents and to synthetic lethality approaches. Moreover, the response can lead to diverse outcomes including apoptosis, senescence, and ferroptosis, which have implications for overcoming drug resistance.
• Camptothecin is a cornerstone of topoisomerase I-targeted cancer therapy, and cellular response mechanisms dictate sensitivity.
• Resistance to camptothecins is a clinical challenge, and understanding GO:0072757 can reveal targets to overcome it.
• ATM and ATR kinases coordinate the DNA damage response to camptothecin, influencing cell survival.
• PARP-1 activation and RND1 transcription contribute to cellular resistance to camptothecin.
• MIB1-mediated degradation of WRN promotes senescence in response to camptothecin.
• Camptothecin can induce ferroptosis in certain cancer contexts, expanding its therapeutic potential.
• Copper-based nanoparticles combined with camptothecin can enhance apoptosis and cuproptosis in triple-negative breast cancer.
• The response is studied in colon cancer cell lines with differential sensitivity to 5-fluorouracil and irinotecan.
• CRISPR screens can identify novel genes regulating the camptothecin response, accelerating drug target discovery.
• Modeling GO:0072757 in vitro helps predict patient responses and design combination therapies.
What Happens During cellular response to camptothecin?
Topoisomerase I trapping and DNA damage induction
In simple terms: Camptothecin sticks to a DNA-unwinding enzyme and prevents it from finishing its job, causing DNA breaks.
Camptothecin binds to the topoisomerase I-DNA cleavage complex and stabilizes it, preventing religation of the single-strand break. During DNA replication, the trapped complex collides with the replication fork, generating double-strand breaks and triggering the DNA damage response. This initial damage is the primary stimulus for GO:0072757.
ATM/ATR-mediated DNA damage signaling
In simple terms: Sensor proteins detect the DNA breaks and send alarm signals to stop the cell cycle and repair damage.
The ATM and ATR kinases are activated in response to camptothecin-induced DNA damage. They phosphorylate downstream effectors such as CHK1 and CHK2, leading to cell cycle arrest and DNA repair or apoptosis. This signaling is a core component of the cellular response to camptothecin.
PARP-1 activation and transcriptional regulation
In simple terms: A repair protein called PARP-1 gets activated and turns on specific genes that help the cell survive.
PARP-1 is activated by DNA strand breaks induced by camptothecin and can modulate transcription. Specifically, PARP-1-dependent transcription of RND1 is induced by topoisomerase I cleavage complexes and confers cellular resistance to camptothecin. This highlights a transcriptional arm of the response.
WRN degradation and senescence
In simple terms: A protein called WRN is destroyed, which can push the cell into a permanent growth arrest called senescence.
MIB1, an E3 ubiquitin ligase, mediates the degradation of WRN helicase in response to camptothecin treatment, promoting cellular senescence. This pathway represents a distinct cell fate outcome within GO:0072757, distinct from apoptosis.
Cell death modalities: apoptosis, ferroptosis, and cuproptosis
In simple terms: Depending on the cell type and context, camptothecin can kill cells through different death programs.
Camptothecin induces apoptosis in many cancer cells, but recent studies show it can also trigger ferroptosis when delivered via specific nanoassemblies. Additionally, copper-based composites combined with camptothecin can induce apoptosis and cuproptosis in triple-negative breast cancer. These diverse death modalities are part of the cellular response.
Key Genes Involved in GO:0072757 cellular response to camptothecin
The following genes and proteins are experimentally implicated in the cellular response to camptothecin, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TOP1 | Topoisomerase I, direct target of camptothecin | Central to drug mechanism; mutations alter sensitivity |
| ATM | DNA damage sensor kinase | Coordinates response to camptothecin-induced breaks |
| ATR | DNA damage sensor kinase | Activates checkpoint signaling upon replication stress |
| PARP1 | Poly(ADP-ribose) polymerase 1 | Modulates transcription and resistance to camptothecin |
| RND1 | Rho GTPase | PARP-1-dependent transcription confers resistance |
| WRN | RecQ helicase | Degraded by MIB1, promotes senescence |
| MIB1 | E3 ubiquitin ligase | Mediates WRN degradation in response to camptothecin |
| TP53 | Tumor suppressor | Frequently mutated in cancers; influences apoptosis |
| BCL2 | Anti-apoptotic protein | Modulates apoptotic response to camptothecin |
| CASP3 | Executioner caspase | Mediates apoptosis |
| GPX4 | Glutathione peroxidase 4 | Inhibits ferroptosis; camptothecin conjugates can trigger ferroptosis |
| SLC7A11 | Cystine/glutamate antiporter | Regulates ferroptosis sensitivity |
| FDX1 | Ferredoxin 1 | Involved in cuproptosis |
| DLAT | Dihydrolipoamide S-acetyltransferase | Cuproptosis marker |
| CHEK1 | Checkpoint kinase 1 | Downstream of ATR; cell cycle arrest |
| CHEK2 | Checkpoint kinase 2 | Downstream of ATM; cell cycle arrest |
| XRCC1 | Base excision repair protein | May influence repair of camptothecin-induced damage |
How Is cellular response to camptothecin Regulated?
The cellular response to camptothecin is regulated at multiple levels. ATM and ATR kinases are activated by DNA damage and phosphorylate downstream effectors to coordinate cell cycle arrest and repair. PARP-1 activity modulates transcription of resistance genes such as RND1. The E3 ubiquitin ligase MIB1 regulates WRN stability, influencing senescence. Additionally, resistance mechanisms include reduced topoisomerase I expression, drug efflux, and altered apoptosis signaling.
cellular response to camptothecin and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TOP1 | Cancer sensitivity to camptothecins | Knockout or point mutation in cancer cell lines |
| PARP1 | Chemoresistance | Knockout and overexpression in colon cancer cells |
| WRN | Senescence and cancer | Knock-in of degradation-resistant mutant |
| GPX4 | Ferroptosis in TNBC | Overexpression or knockout in breast cancer cells |
| FDX1 | Cuproptosis | Knockout in triple-negative breast cancer cells |
Cancer and chemoresistance
Camptothecin derivatives are used to treat colorectal, ovarian, and lung cancers, but resistance often develops. Understanding GO:0072757 can reveal resistance mechanisms, such as PARP-1-dependent RND1 expression or altered WRN degradation. Targeting these pathways may restore sensitivity.
Triple-negative breast cancer
Camptothecin-based nanoassemblies can trigger ferroptosis in triple-negative breast cancer, offering a new therapeutic strategy. Copper-based composites with camptothecin induce apoptosis and cuproptosis, enhancing immune activation. These studies link GO:0072757 to novel cell death modalities.
Colon cancer and differential drug response
Colon cancer cell lines show differential responses to irinotecan (a camptothecin derivative) and 5-fluorouracil, highlighting the clinical relevance of cellular response pathways. Molecular profiling of these responses can guide personalized therapy.
From cellular response to camptothecin-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X mediate camptothecin resistance? | CRISPR knockout in cancer cell lines followed by IC50 assays |
| Does a specific mutation in TOP1 alter drug sensitivity? | Point mutation knock-in via CRISPR |
| Does overexpression of RND1 confer resistance? | CRISPRa or lentiviral overexpression |
| Does WRN degradation require MIB1? | MIB1 knockout and WRN stability assays |
| Can ferroptosis be induced by camptothecin conjugates? | Knockout of GPX4 or SLC7A11 in TNBC cells |
| What genes regulate the camptothecin response genome-wide? | CRISPR library screening with camptothecin selection |
How to Study the cellular response to camptothecin Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Gene function loss | Identify resistance genes |
| CRISPR point mutation | Specific variant effects | Model clinical mutations |
| RNA-seq | Transcriptional changes | Discover induced genes like RND1 |
| Proteomics | Protein stability and modifications | Detect WRN degradation |
| Annexin V/PI staining | Apoptosis | Quantify cell death |
| Beta-galactosidase assay | Senescence | Measure senescence induction |
| CRISPR library screen | Genome-wide fitness | Find novel regulators |
CRISPR knockout and point mutation
CRISPR-Cas9 knockout of candidate genes (e.g., PARP1, WRN, MIB1) followed by camptothecin treatment and viability assays can identify causal roles. Point mutations can model clinically relevant variants in TOP1 or TP53.
Transcriptomics and proteomics
RNA-seq after camptothecin treatment reveals transcriptional changes, such as RND1 induction. Proteomics can detect WRN degradation and post-translational modifications.
Cell death and senescence assays
Apoptosis can be measured by caspase activity or Annexin V staining. Senescence is assessed by beta-galactosidase staining. Ferroptosis and cuproptosis require specific inhibitors and markers.
High-throughput screening
CRISPR library screens with camptothecin selection can identify novel resistance and sensitivity genes. Bioinformatics analysis of screen data pinpoints pathways enriched in GO:0072757.
How CRISPR Can Be Used to Study GO:0072757 cellular response to camptothecin
Knockout
CRISPR knockout of genes such as PARP1 or MIB1 can test their requirement for camptothecin resistance or senescence. Knockout cell lines are generated by indel formation and validated by sequencing and western blot.
Point Mutation
Point mutations in TOP1 or TP53 can be introduced via homology-directed repair to model drug-resistant or sensitive alleles. These models help dissect the contribution of specific residues to camptothecin response.
Knock-in
Knock-in of tagged proteins (e.g., GFP-WRN) allows real-time monitoring of protein stability and localization after camptothecin treatment. Knock-in of resistance alleles can also be used.
Overexpression
Overexpression of candidate resistance genes like RND1 or anti-apoptotic BCL2 can confer camptothecin resistance. CRISPRa or lentiviral systems enable stable overexpression for functional studies.
How EDITGENE Supports cellular response to camptothecin Research
Researchers studying cellular response to camptothecin-related genes often need to determine whether a candidate gene is causally involved in drug sensitivity, resistance, or cell death. EDITGENE provides custom CRISPR cell models and screening services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for cellular response to camptothecin research.
Frequently Asked Questions About cellular response to camptothecin
What is GO:0072757 cellular response to camptothecin?
GO:0072757 is a Gene Ontology biological process term describing all cellular changes triggered by camptothecin, including DNA damage signaling, cell cycle arrest, and cell death.
What genes are involved in cellular response to camptothecin?
Key genes include TOP1, ATM, ATR, PARP1, RND1, WRN, MIB1, TP53, and GPX4, among others.
How does camptothecin cause DNA damage?
Camptothecin traps topoisomerase I on DNA, preventing religation and causing replication fork collisions that generate double-strand breaks.
What is the role of PARP-1 in camptothecin response?
PARP-1 is activated by DNA breaks and can induce transcription of RND1, which confers resistance to camptothecin.
How is WRN involved in camptothecin-induced senescence?
MIB1 ubiquitinates WRN for degradation after camptothecin treatment, promoting cellular senescence.
Can camptothecin induce ferroptosis?
Yes, in certain contexts such as triple-negative breast cancer, camptothecin-peptide conjugates can trigger ferroptosis.
What CRISPR models are used to study camptothecin response?
Knockout, point mutation, knock-in, and overexpression models are used to test gene function in drug sensitivity and resistance.
What is the clinical relevance of GO:0072757?
It relates to the mechanism of camptothecin-based chemotherapies and resistance mechanisms in cancers like colon and breast cancer.
How does ATM/ATR signaling respond to camptothecin?
ATM and ATR are activated by camptothecin-induced DNA damage and phosphorylate downstream effectors to arrest the cell cycle.
What methods study cellular response to camptothecin?
CRISPR screens, RNA-seq, proteomics, apoptosis and senescence assays are commonly used.
Conclusion
GO:0072757 cellular response to camptothecin is a critical biological process that determines the efficacy of topoisomerase I-targeted cancer therapies. The pathways involved, from ATM/ATR signaling to PARP-1-dependent transcription and WRN degradation, offer numerous targets for overcoming resistance. CRISPR-based models and screening services from EDITGENE empower researchers to dissect these mechanisms and accelerate drug discovery.
References
- 1. Wang N et al.. 2024. Copper-Based Composites Nanoparticles Improve Triple-Negative Breast Cancer Treatment with Induction of Apoptosis-Cuproptosis and Immune Activation.. Adv Healthc Mater 13(28):e2401646 PMID: 39001628
- 2. Li M et al.. 2020. MIB1-mediated degradation of WRN promotes cellular senescence in response to camptothecin treatment.. FASEB J 34(9):11488-11497 PMID: 32652764
- 3. Thomas CJ et al.. 2004. Camptothecin: current perspectives.. Bioorg Med Chem 12(7):1585-604 PMID: 15028252
- 4. Haug K et al.. 2008. Cellular response to irinotecan in colon cancer cell lines showing differential response to 5-fluorouracil.. Anticancer Res 28(2A):583-92 PMID: 18506996
- 5. Beretta GL et al.. 2006. Mechanisms of cellular resistance to camptothecins.. Curr Med Chem 13(27):3291-305 PMID: 17168852
- 6. Mouly L et al.. 2018. PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin.. Cell Death Dis 9(9):931 PMID: 30209297
- 7. Zuco V et al.. 2010. ATM- and ATR-mediated response to DNA damage induced by a novel camptothecin, ST1968.. Cancer Lett 292(2):186-96 PMID: 20042274
- 8. Zhang W et al.. 2026. In situ delivery of JPH203 via camptothecin-peptide conjugate nanoassemblies to trigger ferroptosis in triple-negative breast cancer.. J Control Release 393:114829 PMID: 41839266
